Evidence has shown that the absence of CDR1as is directly associated with the heightened metastatic potential of melanoma cells, while cells expressing higher levels of CDR1as demonstrate increased sensitivity to GPX4 inhibitors (181). The gene discussed is GPX4; the disease is melanoma.